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Commentary  
With interest we read the review article by Mahalakshmi et al. about the repercussions of an 
infection with SARS-CoV-2 (COVID
concluded that neurons and glial cells express ACE2
contribute to neuroinflammation, and that SARS
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have the following comments and concerns. 
The main limitation of the review is that it is assumed that CNS compromise from 
SARS-CoV-2 only results from invasion of the virus in the CNS or the response of the immune 
system against the virus [1]. However, the infection may not only result in primary damage 
of neurons or glial cells by the invasion of the virus or secondary due to the reaction of the 
global immune system or glial cells to the viral attack, but also tertiary due to primary or 
secondary affection of organs other than the CNS, which may lead to tertiary CNS 
compromise due to the close connection between the CNS and these other affected organs. 
The organ most closely connected to the CNS is the heart. This is why primary or secondary 
affection of the heart by SARS-CoV-2 can lead to CNS disease. Affection of the kidneys may 
cause renal hypertension, which may be responsible for intracerebral bleeding or ischemic 
stroke. Gastro-intestinal involvement may lead to electrolyte disturbances and consecutively 
to arterial hypertension [2].  
A pathophysiological mechanism of ischemic stroke in COVID-19 patients not 
considered is cardiac embolism. There are several reports showing the SARS-CoV-2 may 
cause myocarditis [3, 4]. Since myocarditis may go along with intra-cardiac thrombus 
formation [5], it is conceivable that intra-cardiac thrombi are transported to cerebral arteries 
where they may occlude small or large intra-cerebral arteries. Intra-ventricular thrombi may 
also result from heart failure. Since myocarditis may be complicated by arrhythmias, 
including atrial fibrillation [6], it is conceivable that cardio-embolism may also originate from 
the left atrium due to impaired contractility.  
Another source of cardio-embolism not addressed in the review is Takotsubo 
syndrome (TTS). There is an increasing number of reports demonstrating that SARS-CoV-2 
can trigger TTS [7]. Since TTS is attributed in one third of the cases to emotional triggers and 
in another third to physical triggers, it is conceivable that TTS in SARS-CoV-2 infected 
patients is triggered by anxiety or by stress from hypoxia, dyspnoea, or mechanical 
ventilation.  
The spectrum of CNS disease associated with a SARS-CoV-2 infection is broader than 
anticipated in the review. SARS-CoV-2 may not only induce cerebrovascular disease, 
demyelinating CNS, or neurodegenerative disease, but also virus-related 
meningitis/encephalitis, immune encephalitis, myoclonus-ataxia syndrome, immune-
response related myelitis, acute, disseminated encephalomyelitis (ADEM), sinus venous 
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thrombosis (SVT), vasoconstriction syndrome, cerebral vasculitis, intracerebral bleeding, 
psychosis, epilepsy, or headache. Among the demyelinating CNS disorders, SARS-CoV-2 may 
even precipitate multiple sclerosis [8]. 
Overall, the appealing review about pathophysiologic mechanisms involved in the 
development of CNS disease due to SARS-CoV-2 has several limitations. Tertiary causes of 
CNS disease, particularly cardiologic involvement, should be considered in the discussion 
about the pathophysiology of CNS compromise in COVID-19 patients. Particularly, cardio-
embolism should be added to the discussion. There are also a number of CNS disorders, 
which are not explained by the pathophysiological scenarios depicted in the review. 
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